T2 Biosystems Inc. and Allergan PLC are teaming up to develop a diagnostic panel to detect Gram-negative bacteria and antibiotic resistance in patients with serious bacterial infections, including those that result in sepsis. (Nov.)
Allergan will pay $4mm in milestones tied to the development of the bacterial resistance panel and an expansion of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?